Axon Dx LLC Profile last edited on: 3/26/21
CAGE: 7CCH7
UEI: MTLNDGKGVNX7
Business Identifier: Imaging technologies for rare cancer cells 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 05
County: Albemarle
Congr. District: 05
County: Albemarle
Public Profile
Axon DX LLC develops imaging technologies and products for the identification and research of rare cancer cells such as circulating tumor cells and circulating endothelial cells. The firm's primary platform, nCyte, is a research tool that allows for morphological and targets molecular characterization of Circulating Rare Cells. The platform offers enhanced scanning optical systems powered by AI and utilizes biomarkers for enhanced insight.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NSF | $1,224,128 | |
| Project Title: Development of AI Software to Capture and Identify Circulating Rare Cells in Lung Patients | ||||
Key People / Management
Kent Murphy -- CEO
Yongjian Yu
Yongjian Yu
